Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical has shown significant trading activity, with a notable increase in financing buy-ins and a high financing balance relative to its market value [1] - On December 24, Duorui Pharmaceutical's stock rose by 2.09%, with a trading volume of 59.29 million yuan and a net financing buy of 4.89 million yuan [1] - The company's financing balance reached 214 million yuan, accounting for 5.09% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period, while the average circulating shares per person increased by 19.90% to 12,576 shares [2] - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%, and a net profit attributable to shareholders of -79.73 million yuan, representing a significant decline of 366.82% [2] - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2]
多瑞医药12月24日获融资买入1122.67万元，融资余额2.14亿元